60 research outputs found
PHARMACEUTICAL STANDARDIZATION OF JATIPHALADYA VATI
Standardization is the process of developing and agreeing upon technical standards. A standard is a document that establishes uniform engineering or technical specifications, criteria, methods, processes or practices. Many drugs are described in Ayurvedic classical texts for the treatment of various disorders. Jatiphaladya Vati is one such Kharaliya Rasayana mentioned in Rasendra Saara Samgraha, indicated in Arshas (Haemorrhoids). Jatiphala (Myristica fragrans Houtt.), Lavanga (Syzygium aromaticum), Pippali (Piper longum), Saindhava lavana (Rock salt), Shunthi (Zingiber officinale Roxb), Dhattura beeja (Datura metel Linn.), Hingula (Cinnabar) and Tankana (Borax) are the main ingredients. Shodhana (Purification), Churna nirmana (Preparation of powder), Bhavana (Soaking with liquid and triturating till drying) and Mardana (Trituration) are the important steps involved in preparation of Jatiphaladya Vati. Shodhana of Hingula, Tankana and Dhattura beeja was carried out by classical method to remove the impurities. Churna of all above ingredients were prepared by subjecting it to grinding in Khalwa yantra and filtering through cloth. All ingredients were mixed properly to make homogenous mixture; later on it was triturated with Nimbu swarasa to obtain 250 mg tablets (brick red in colour) in tablet compression machine. The present study has been planned to standardize the method of preparation of an important Herbo-mineral formulation i.e. Jatiphaladya Vati
STANDARDIZATION OF YOGAAMRUTO RASA BY USING MODERN ANALYSIS TECHNIQUES
Rasa Shastra is a partially independent branch of Ayurvedic medicine, which deals with preparation of the drugs with metals and minerals to produce the drugs with higher efficacy in lower dose with good palatability. Yogaamruto Rasa (YMR) is one such Rasoushadhi mentioned in Rasa Kamdhenu indicated for all types of Kushta. Parada, Gandhaka, Tamra churna, Vatsanabha, Vacha, Trikatu, Musta and Vidanga are the main ingredients of YMR. Shodhana, Mardana, Murchchana, Pishti nirmana, Aagni paaka are the important steps involved in preparation of YMR. Till date no standards are available for the above drug. Need of the hour is to revalidate the safety and efficacy of the above said formulation. In the current study of YMR it was subjected to analysis through X-ray diffraction (XRD), Scanning electron microscope (SEM), Energy dispersive X-ray spectroscopy (EDX) and Zeta potential (ZP). XRD of YMR reveals that major peaks are of Cu20 (Cuprite) and minor peaks of HgS (Meta Cinnabar), Cu2S (Cuprous Sulphide). SEM study found the smallest grain size ranging between115nm at 5Kx magnification to 82.11 nm at 7Kx magnification. EDX study reveals that YMR contains significant percentage of O-25.96%, Cu-22.82%, C-20.41%, Hg- 12.84 %, S- 9.8%. w/w. ZP mean value for YMR is 51.4 mV which indicates moderate colloidal stability.
ANTIOXIDANT AND ANTIPROLIFERATIVE POTENTIALS OF MARINE ACTINOMYCETES
Objective: The aim of present studyis to isolate and characterize a novel actinomycetes strain from marine sediments collected at Kakinada coast. To evaluate antioxidant and antiproliferative activities of the crude methanolic extract of isolated actinomycetes.Methods: Actinomycetes was isolated from marine sediments collected at Kakinada coast using starch casein agar. Morphological, biochemical and molecular characterization was performed and the crude methanolic extract was used for determination of in vitro antioxidant activity and antiproliferative activity against MDA-MB 231 breast cancer cells.Results: The crude methanolic extract exhibited significant antioxidant activity with ICĂÂ50Ă value in the range of 30-46 Ă”g/ml in different radical scavenging assays. Moreover, the extract showed concentration dependent cytotoxicity against triple negative breast cancer cell line, MDA-MB 231 with IC50 of 42.5Ă”g/ml. The extract also inhibited cell proliferation with IC50 value 44.1 Ă”g/ml probably by arresting cell cycle at S phase. The antioxidant activity of the extract was strongly correlated with cytotoxic and antiproliferative activity.Conclusion: The isolated marine actinomycetes can be the potential source of antioxidants with the anticancer property
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1ÎČ, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1ÎČ innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
Global, regional, and national burden of disorders affecting the nervous system, 1990â2021: a systematic analysis for the Global Burden of Disease Study 2021
BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378â521), affecting 3·40 billion (3·20â3·62) individuals (43·1%, 40·5â45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7â26·7) between 1990 and 2021. Age-standardised rates of deaths per 100â000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6â38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5â32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7â2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990â2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56â604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100â000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100â000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100â000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100â000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100â000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTICâHF: baseline characteristics and comparison with contemporary clinical trials
Aims:
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTICâHF) trial. Here we describe the baseline characteristics of participants in GALACTICâHF and how these compare with other contemporary trials.
Methods and Results:
Adults with established HFrEF, New York Heart Association functional class (NYHA)ââ„âII, EF â€35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokineticâguided dosing: 25, 37.5 or 50âmg bid). 8256 patients [male (79%), nonâwhite (22%), mean age 65âyears] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NTâproBNP 1971âpg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTICâHF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressureâ<â100âmmHg (n = 1127), estimated glomerular filtration rate <â30âmL/min/1.73 m2 (n = 528), and treated with sacubitrilâvalsartan at baseline (n = 1594).
Conclusions:
GALACTICâHF enrolled a wellâtreated, highârisk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation
Tantalum oxide films prepared by unbalanced reactive magnetron sputtering
Good quality tantalum oxide films with a refractive index of 2.10 and an absorption coefficient less than 10-4 were prepared using unbalanced reactive magnetron sputtering. The ion bombardment due to the unbalanced magnetron sputtering enabled this deposition at substrate temperatures as low as 250 Ă°C. Another effect of ion bombardment is deposition of mixed phase crystalline films even at room temperature. The low substrate temperature deposition is of significance due to the fact that tantalum oxide films can be used as antireflection coating on silicon solar cells to enhance the performance and for this purpose lower substrate temperatures are essential
Not Available
Not AvailableIN THIS PAPER THE AUTHORS REVIEW THE EXISTING APPROACHES VIS- A - VIS TECHNOLOGICAL OPTIONS AVAILABLE AND NEW DEMANDS EMERGED IN THE FIELD OF SOIL AND WATER CONSERVATION . ESTABLISHMENT OF SOIL CONSERVATION UNITS FOR PLANNING AND IMPLEMENTING THE EROSION CONTROL WORKS HAVE BEEN SUGGESTED. THE FUTURE STRATEGY ON THIS BASIS FOR A SUSTAINABLE LAND PRODUCTIVITY HAS ALSO BEEN DISCUSSED.Not Availabl
Sensor fault detection in structural health monitoring using null subspaceâbased approach
- âŠ